St Mark's Hospital, London, UK.
Curr Opin Clin Nutr Metab Care. 2018 Sep;21(5):405-410. doi: 10.1097/MCO.0000000000000488.
The purpose of this article is to provide an update on recent developments in fecal microbiota transplantation (FMT) in the last year.
Although FMT is an accepted treatment for recurrent Clostridium difficile infection (CDI), recently it is also gaining acceptance for the treatment of refractory CDI. FMT is showing promise in ulcerative colitis and is experimental in many other conditions. The optimal practical aspects to enhance the success of FMT are still being established.
The implication of current research is that the indications of FMT may be extended to other conditions in the future.
本文旨在提供过去一年中粪便微生物群移植（FMT）最新进展的更新。
尽管 FMT 是复发性艰难梭菌感染（CDI）的一种公认治疗方法，但最近它也被越来越多地接受用于治疗难治性 CDI。FMT 在溃疡性结肠炎中显示出前景，并且在许多其他疾病中处于实验阶段。为了提高 FMT 的成功率，目前仍在确定最佳的实际方面。
目前的研究表明，FMT 的适应证可能在未来会扩展到其他疾病。
